Eyenovia, Inc. (EYEN) News
Filter EYEN News Items
EYEN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest EYEN News From Around the Web
Below are the latest news stories about EYENOVIA INC that investors may wish to consider to help them evaluate EYEN as an investment opportunity.
7 Promising Penny Stocks With the Potential to Defy ExpectationsYou know you want it. |
Eyenovia, Inc. (NASDAQ:EYEN) Q3 2023 Earnings Call TranscriptEyenovia, Inc. (NASDAQ:EYEN) Q3 2023 Earnings Call Transcript November 13, 2023 Operator: Good day, ladies and gentlemen. And welcome to Eyenovia’s Third Quarter of 2023 Earnings Conference Call. At this time, all participants are in listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder this conference is being recorded. I will […] |
Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business UpdateAcquired U.S. commercial rights to APP13007, currently under FDA review for post-surgical ocular pain and inflammation, from Formosa Pharmaceuticals Announced FDA approval of Coastline International as contract manufacturer for Mydcombi cartridge subassemblies and preparations for national launch Company to host conference call and webcast today, November 13th, at 4:30 pm ET NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage, topical ophthalmic company |
4 Biotech Stocks Likely to Outpace Q3 Earnings EstimatesLet us look at a few biotech companies, ACLX, LEGN, GRCL and EYEN, which are poised to beat third-quarter earnings estimates. |
Eyenovia to Report Third Quarter 2023 Results on Monday, November 13Company to host an investor conference call and webcast at 4:30pm EDTNEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ for mydriasis, preparing for regulatory approval of APP13007 for relief of pain and inflammation post ocular surgery, and incorporating its advanced Optejet® device with late-stage product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indicatio |
Eyenovia Announces FDA Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial ProductionAnticipates having product available to ship in January 2024NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ for mydriasis, preparing for regulatory approval of APP13007 for relief of pain and inflammation post ocular surgery, and incorporating its advanced Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayIt's time to dive into the biggest pre-market stock movers as we start the trading week on Monday with the hottest coverage! |
Billionaire Marc Lasry’s Top 10 Stock PicksIn this piece, we will take a look at billionaire Marc Lasry’s top ten stock picks. If you want to skip our introduction to the billionaire hedge fund boss and the general investing climate, then take a look at Billionaire Marc Lasry’s Top 5 Stock Picks. Marc Lasry is a hedge fund billionaire who started […] |
Eyenovia to Sponsor Course on Drug Delivery Innovation at IJCAHPO’s 51st Annual Continuing Education (ACE) ProgramCourse to provide ophthalmic technicians with background on the Optejet dispensing technology and training on the use of Mydcombi™ for mydriasis NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ for mydriasis, preparing for regulatory approval of APP130007 for relief of pain and inflammation post ocular surgery, and incorporating its advanced Optejet® device for use both in connection with its own drug-device the |
Eyenovia to Present Data on Preservative-Free Microbial Integrity of the Optejet®In rigorous testing, the Optejet remained contaminant-free when subjected to a microbial load that exceeds typical environmental conditions Presentation to be made at the American Academy of Optometry’s “Academy 2023 New Orleans” Annual Meeting NEW YORK, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ for mydriasis, preparing for regulatory approval of APP13007 for relief of pain and inflammation post ocular surgery, and |